Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail opens new front in Andrx diltiazem dispute

Executive Summary

"As a result of preliminary testing to date, Biovail has given notice to Andrx that its Cartia XT product may be infringing the agreed upon dissolution specifications" contained in the Stipulation and Agreement originally signed between Andrx and Aventis. Cartia XT is a generic version of Cardizem CD; Biovail acquired rights to the Aventis brand in January (1"The Pink Sheet" Jan. 8, p. 21). Andrx launched Cartia XT after settling a patent dispute with Aventis; the settlement is the subject of a pending Federal Trade Commission administrative action

You may also be interested in...



Andrx Generic Tiazac Open For Approval; Court Lifts 30-Month Stay

The stay of approval on Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) will be lifted Sept. 27, Miami federal court Judge William Dimitrouleas ruled Sept. 19.

Andrx Generic Tiazac Open For Approval; Court Lifts 30-Month Stay

The stay of approval on Andrx' generic version of Biovail/Forest's Tiazac (diltiazem) will be lifted Sept. 27, Miami federal court Judge William Dimitrouleas ruled Sept. 19.

Biovail Buys Old Cardizem Name For New Diltiazem Product

Biovail's purchase of Aventis' Cardizem line will allow the company to market its once-daily diltiazem under an established brand name.

UsernamePublicRestriction

Register

PS037349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel